v3.24.2.u1

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	$ 650,222	$ 333,351	$ 853,495	$ 384,780
Operating expenses:
Research and development	2,588,316	2,681,898	6,144,178	6,700,557
General and administrative	2,024,473	2,670,363	4,462,777	5,789,579
Total operating expenses	4,612,789	5,352,261	10,606,955	12,490,136
Loss from operations	(3,962,567)	(5,018,910)	(9,753,460)	(12,105,356)
Other income (expense):
Interest income, net	43,819	36,120	99,568	71,199
Change in fair value of note receivable	(560,473)	(37,416)	(560,473)	(37,416)
Total other income (expense), net	(516,654)	(1,296)	(460,905)	33,783
Net loss	$ (4,479,221)	$ (5,020,206)	$ (10,214,365)	$ (12,071,573)
Net loss per share, basic (in Dollars per share)	$ (1.22)	$ (3.47)	$ (3.37)	$ (8.34)
Weighted average common shares outstanding, basic (in Shares)	3,667,264	1,447,723	3,027,585	1,447,723
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (4,479,221)	$ (5,020,206)	$ (10,214,365)	$ (12,071,573)
Other comprehensive loss:
Foreign currency translation adjustments	19,024	(7,566)	(36,571)	(26,235)
Comprehensive loss	$ (4,460,197)	$ (5,027,772)	$ (10,250,936)	$ (12,097,808)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5

TFF Pharmaceuticals, Inc. 10-Q